Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/ https://www.ncbi.nlm.nih.gov/pubmed/29020411 http://dx.doi.org/10.1093/eurheartj/ehx450 |
_version_ | 1783339943501758464 |
---|---|
author | Ference, Brian A Cannon, Christopher P Landmesser, Ulf Lüscher, Thomas F Catapano, Alberico L Ray, Kausik K |
author_facet | Ference, Brian A Cannon, Christopher P Landmesser, Ulf Lüscher, Thomas F Catapano, Alberico L Ray, Kausik K |
author_sort | Ference, Brian A |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6047439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60474392018-07-19 Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration Ference, Brian A Cannon, Christopher P Landmesser, Ulf Lüscher, Thomas F Catapano, Alberico L Ray, Kausik K Eur Heart J Current Opinion Oxford University Press 2018-07-14 2017-08-14 /pmc/articles/PMC6047439/ /pubmed/29020411 http://dx.doi.org/10.1093/eurheartj/ehx450 Text en © The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Current Opinion Ference, Brian A Cannon, Christopher P Landmesser, Ulf Lüscher, Thomas F Catapano, Alberico L Ray, Kausik K Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title | Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title_full | Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title_fullStr | Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title_full_unstemmed | Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title_short | Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
title_sort | reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (pcsk9) inhibitors and statins: an analysis of fourier, spire, and the cholesterol treatment trialists collaboration |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/ https://www.ncbi.nlm.nih.gov/pubmed/29020411 http://dx.doi.org/10.1093/eurheartj/ehx450 |
work_keys_str_mv | AT ferencebriana reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration AT cannonchristopherp reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration AT landmesserulf reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration AT luscherthomasf reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration AT catapanoalbericol reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration AT raykausikk reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration |